Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
- PMID: 8346443
- DOI: 10.1126/science.8346443
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
Abstract
The apolipoprotein E type 4 allele (APOE-epsilon 4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE-epsilon 4 alleles in 42 families with late onset AD. Thus APOE-epsilon 4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE-epsilon 4 was virtually sufficient to cause AD by age 80.
Comment in
-
New piece in Alzheimer's puzzle.Science. 1993 Aug 13;261(5123):828-9. doi: 10.1126/science.8346434. Science. 1993. PMID: 8346434 No abstract available.
Similar articles
-
Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):515-7. doi: 10.1136/jnnp.2005.063917. J Neurol Neurosurg Psychiatry. 2006. PMID: 16543533 Free PMC article.
-
Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region.Hum Mol Genet. 1994 Apr;3(4):569-74. doi: 10.1093/hmg/3.4.569. Hum Mol Genet. 1994. PMID: 8069300
-
Allele doses of apolipoprotein E type epsilon 4 in sporadic late-onset Alzheimer's disease.Am J Med Genet. 1995 Dec 18;60(6):566-9. doi: 10.1002/ajmg.1320600617. Am J Med Genet. 1995. PMID: 8825898
-
[Apolipoprotein E4 and late-onset Alzheimer's disease].Nihon Rinsho. 1994 Dec;52(12):3257-65. Nihon Rinsho. 1994. PMID: 7853720 Review. Japanese.
-
Amyloid beta-protein, APOE genotype and head injury.Ann N Y Acad Sci. 1996 Jan 17;777:271-5. doi: 10.1111/j.1749-6632.1996.tb34431.x. Ann N Y Acad Sci. 1996. PMID: 8624097 Review.
Cited by
-
The Immune System as a Therapeutic Target for Alzheimer's Disease.Life (Basel). 2022 Sep 16;12(9):1440. doi: 10.3390/life12091440. Life (Basel). 2022. PMID: 36143476 Free PMC article. Review.
-
The Effect of GBA Mutations and APOE Polymorphisms on Dementia with Lewy Bodies in Ashkenazi Jews.J Alzheimers Dis. 2021;80(3):1221-1229. doi: 10.3233/JAD-201295. J Alzheimers Dis. 2021. PMID: 33646158 Free PMC article.
-
Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection.Annu Rev Clin Psychol. 2013;9:621-48. doi: 10.1146/annurev-clinpsy-050212-185535. Epub 2013 Jan 7. Annu Rev Clin Psychol. 2013. PMID: 23297785 Free PMC article. Review.
-
Activation of PARP by oxidative stress induced by β-amyloid: implications for Alzheimer's disease.Neurochem Res. 2012 Nov;37(11):2589-96. doi: 10.1007/s11064-012-0895-x. Epub 2012 Oct 18. Neurochem Res. 2012. PMID: 23076628 Review.
-
Morphometric and histologic substrates of cingulate integrity in elders with exceptional memory capacity.J Neurosci. 2015 Jan 28;35(4):1781-91. doi: 10.1523/JNEUROSCI.2998-14.2015. J Neurosci. 2015. PMID: 25632151 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous